Prevalence of Pharyngolaryngeal Reflux in Patients Treated for Obstructive Sleep Apnea Syndrome

NCT ID: NCT05110352

Last Updated: 2022-10-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

37 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-03-24

Study Completion Date

2022-04-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to find, using validated and efficient tools, a laryngopharyngeal reflux in patients receiving polysomnography for suspected obstructive sleep apnea syndrome.

It is proposed to carry out simultaneously, at the Sleep Center of the Polyclinique of Poitiers (CSPP), a polysomnography, a 24-hour Restech pharyngeal pH-metry (day and night), a Peptest (in the evening and in the morning of the polysomnography), with the RSS-12 questionnaire and the RSA score.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obstructive Sleep Apnea Reflux, Laryngopharyngeal

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Obstructive Sleep Apnea Syndrome patients with polysomnography planned

Apnea-Hypopnea Index (AHI) \> 15

Group Type EXPERIMENTAL

Polysomnography

Intervention Type DIAGNOSTIC_TEST

A polysmnography is planned for every patients in order to evaluate the Apnea-Hypopnea Index (AHI).

Pharyngeal ph-metry Restech

Intervention Type DIAGNOSTIC_TEST

Pharyngeal ph-metry Restech over 24 hours (night and day)

Peptest

Intervention Type PROCEDURE

Saliva sample to look for an association between pharyngolaryngeal reflux and obstructive sleep apnea syndrome

Questionnaire RSS-12

Intervention Type BEHAVIORAL

Questionnaire with 12 items about quality of life. Score between 0 and 5.

Reflux Sign Assessment

Intervention Type PROCEDURE

RSA score about anatomy and morphology of the mouth

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Polysomnography

A polysmnography is planned for every patients in order to evaluate the Apnea-Hypopnea Index (AHI).

Intervention Type DIAGNOSTIC_TEST

Pharyngeal ph-metry Restech

Pharyngeal ph-metry Restech over 24 hours (night and day)

Intervention Type DIAGNOSTIC_TEST

Peptest

Saliva sample to look for an association between pharyngolaryngeal reflux and obstructive sleep apnea syndrome

Intervention Type PROCEDURE

Questionnaire RSS-12

Questionnaire with 12 items about quality of life. Score between 0 and 5.

Intervention Type BEHAVIORAL

Reflux Sign Assessment

RSA score about anatomy and morphology of the mouth

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults (\> 18 ans)
* Polysomnography planned for OSA assessment
* RPL known or not, suspected or not
* Affiliation to a social security scheme or beneficiary of such a scheme
* Patient having signed the free and informed consent

Exclusion Criteria

* Minors
* Smoking, alcoholism, chronic or serious disabling pathology
* Medical history of upper aerodigestive tract cancer, radiotherapy
* Recent infection of upper aerodigestive tract, chronic rhinosinusitis
* Permanent nasal obstruction
* Active allergy
* Non-obstructive SAS (central)
* Patient under anti-secretory treatment (IPP) during the 8 days preceding the Restech associated with the PSG
* Refusal to participate in the study
* Protected patients: Adults under guardianship, guardianship or other legal protection, deprived of liberty by judicial or administrative decision
* Pregnant, breastfeeding or parturient
* Hospitalized without consent
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Elsan

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre du Sommeil de la Polyclinique de Poitiers

Potiers, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2020-A02789-30

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.